Therese‐Marie Stachyra

Author

Also Known As

T. Stachyra, Therese Stachyra, Therese Valat-Stachyra, Therese-Marie Stachyra, Therese‐Marie Stachyra, Thérèse Stachyra, Thérèse Stachyra, Thérèse Stachyra Valat, Thérèse Stachyra-Valat, Thérèse Valat

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis Institutes for BioMedical Research Friedrich Miescher Institute Peptidream (Japan)Centre National de la Recherche Scientifique

About

Therese‐Marie Stachyra is an author at Novartis (Switzerland) specializing in medicine, drug discovery, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	743
2	Natural Sciences	8	8	583
3	Biochemistry	8	8	459
4	Engineering	2	2	93
5	Biomolecular Engineering	2	2	46

Therese‐Marie Stachyra

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors Philipp Holzer, Keiichi Masuya, Pascal Furet, Journal of Medicinal Chemistry Dihydroisoquinolinone DerivativeDrug TargetMolecular BiologyPharmacotherapyTumor Biology	2015	202
In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases Therese‐Marie Stachyra, Premavathy Levasseur, Marie-Claude Péchereau, Journal of Antimicrobial Chemotherapy	2009	171
Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases Michael T. Black, Therese‐Marie Stachyra, Denis Platel, Antimicrobial Agents and Chemotherapy	2008	141
Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase Inhibitor Therese‐Marie Stachyra, Marie-Claude Péchereau, Jean‐Michel Bruneau, Antimicrobial Agents and Chemotherapy Mechanistic StudiesAntimicrobial ChemotherapyChemical BiologyPharmaceutical ChemistryDrug Resistance	2010	140
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201 Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Cancer Research	2018	85
Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument Pascal Furet, Keiichi Masuya, Joerg Kallen, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryDrug TargetBiochemistryP53–mdm2 Interaction	2016	77
PAX8 and MECOM are interaction partners driving ovarian cancer Melusine Bleu, Fanny Mermet‐Meillon, Verena Apfel, Nature Communications	2021	77
The central valine concept provides an entry in a new class of non peptide inhibitors of the p53–MDM2 interaction Pascal Furet, Patrick Chêne, Alain De Pover, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryP53–mdm2 InteractionMedicineRational Drug Design	2012	73
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance Martin Schröder, Martin Renatus, Xiaoyou Liang, Nature Communications	2024	71
Fluorescence Detection-Based Functional Assay for High-Throughput Screening for MraY Therese‐Marie Stachyra, C. Dini, Paul Ferrari, Antimicrobial Agents and Chemotherapy Synthetic Mray InhibitorsEngineeringEscherichia ColiBiosynthesisBioanalysis	2004	69

Page 1